• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Protein Synthesis, Modification & Degradation
You are here: Product Lines > Oxidative Stress > Protein Synthesis, Modification & Degradation
 
Toolbar - View Selection
 
 Items 1-20 of 608 Page 1 of 31 Select Page: 1 2 3 4 5 6 7 8 9 10  >>  
ALX-106-001 Revised 30-Nov-06
L-NMMA . monoacetate
Add to Clipboard
SYNONYMS NG-Monomethyl-L-arginine . monoacetate
PRODUCT LINE Nitric Oxide Pathway
PRODUCT CATEGORY NOS Inhibitors (NOS Induction & Enzyme Activity)
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-106-001-M005   5 mg 20.00 USD Add To Cart
ALX-106-001-M025   25 mg 55.00 USD Add To Cart
ALX-106-001-M100   100 mg 180.00 USD Add To Cart
ALX-106-001-G001   1 g 360.00 USD Add To Cart
Product Specification
FORMULA: C7H16N4O2 . CH3COOH
MW: 188.2 . 60.1
CAS NUMBER: 53308-83-1
PURITY: ≥99%
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C

Product Description
Standard inhibitor of nitric oxide synthase. Suppresses the release of nitric oxide from endothelial cells.
Product Specific Literature References
Identification of arginine as a precursor of endothelium-derived relaxing factor: I. Sakuma, et al.; PNAS 85, 8664 (1988) Abstract
A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation: D.D. Rees, et al.; Br. J. Pharmacol. 96, 418 (1989) Abstract
Endogenous NO regulates superoxide production at low oxygen concentrations by modifying the redox state of cytochrome c oxidase: M. Palacios-Callender, et al.; PNAS 101, 7630 (2004) Abstract; Full Text
Further Categories Containing This Product:
PRMTs, Mono- & Dimethylarginine / Related Products
 
 
ALX-106-002 Revised 03-Jun-03
D-NMMA . monoacetate
Add to Clipboard
SYNONYMS NG-Monomethyl-D-arginine . monoacetate
PRODUCT LINE Nitric Oxide Pathway
PRODUCT CATEGORY NOS Inhibitors (NOS Induction & Enzyme Activity)
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-106-002-M005   5 mg 27.00 USD Add To Cart
ALX-106-002-M025   25 mg 100.00 USD Add To Cart
ALX-106-002-M100   100 mg 280.00 USD Add To Cart
Product Specification
FORMULA: C7H16N4O2 . CH3COOH
MW: 188.2 . 60.1
CAS NUMBER: 137694-75-8
PURITY: ≥99%
APPEARANCE: White solid.
SOLUBILITY: Soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C

Further Categories Containing This Product:
PRMTs, Mono- & Dimethylarginine / Related Products
 
 
ALX-106-005 Revised 24-Feb-05
NG, NG-Dimethyl-L-arginine . di(p-hydroxyazobenzene-p'-sulfonate)
Add to Clipboard
SYNONYMS ADMA . 2HABS
H-Arg(di-Me)-OH . 2HABS (asymmetrical)
PRODUCT LINE Nitric Oxide Pathway
PRODUCT CATEGORY NOS Inhibitors (NOS Induction & Enzyme Activity)
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-106-005-M005   5 mg 23.00 USD Add To Cart
ALX-106-005-M025   25 mg 55.00 USD Add To Cart
Product Specification
FORMULA: C8H18N4O2 . 2C12H10N2O4S
MW: 202.2 . 556.6
PURITY: ≥97%
APPEARANCE: Orange powder.
SOLUBILITY: Soluble in methanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.

Product Description
Inhibits nitric oxide synthesis. This salt form is more stable than the dihydrochloride.
Product Specific Literature References
L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells: J.B. Hibbs Jr., et al.; J. Immunol. 138, 550 (1987) Abstract
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure: P. Vallance, et al.; Lancet 339, 572 (1992), and references cited therein. Abstract
Further Categories Containing This Product:
PRMTs, Mono- & Dimethylarginine / Related Products
 
 
ALX-106-006 Revised 15-Oct-07
NG, NG-Dimethyl-L-arginine . dihydrochloride
Add to Clipboard
SYNONYMS H-Arg(di-Me)-OH . 2HCl (asymmetrical)
ADMA . 2HCl
PRODUCT LINE Nitric Oxide Pathway
PRODUCT CATEGORY NOS Inhibitors (NOS Induction & Enzyme Activity)
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-106-006-M005   5 mg 33.00 USD Add To Cart
ALX-106-006-M025   25 mg 85.00 USD Add To Cart
Product Specification
FORMULA: C8H18N4O2 . 2 HCl . H2O
MW: 202.2 . 73.0 . 18.0
PURITY: ≥97%
APPEARANCE: White to off-white crystalline solid.
SOLUBILITY: Soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Stock solutions are stable for up to 4 months when stored at -20°C.
HANDLING: Hygroscopic.

Product Description
Endogenous nitric oxide synthase (NOS) inhibitor.
Product Specific Literature References
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure: P. Vallance, et al.; Lancet 339, 572 (1992), and references cited therein. Abstract
Further Categories Containing This Product:
PRMTs, Mono- & Dimethylarginine / Related Products
 
 
ALX-106-007 Revised 03-Feb-05
NG, N'G-Dimethyl-L-arginine . di(p-hydroxyazobenzene-p'-sulfonate)
Add to Clipboard
SYNONYMS SDMA . 2HABS
H-Arg(di-Me)-OH . 2HABS (symmetrical)
PRODUCT LINE Nitric Oxide Pathway
PRODUCT CATEGORY NOS Inhibitors (NOS Induction & Enzyme Activity)
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-106-007-M005   5 mg 23.00 USD Add To Cart
ALX-106-007-M025   25 mg 55.00 USD Add To Cart
Product Specification
FORMULA: C8H18N4O2 . 2C12H10N2O4S
MW: 202.2 . 556.6
CAS NUMBER: 102783-24-4
PURITY: ≥97%
APPEARANCE: Orange powder.
SOLUBILITY: Soluble in methanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.

Product Description
Has been shown not to inhibit nitric oxide synthesis, both in vitro and in vivo. This salt form is more stable than the dihydrochloride.
Product Specific Literature References
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure: P. Vallance, et al.; Lancet 339, 572 (1992), and references cited therein.
L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells: J.B. Hibbs Jr., et al.; J. Immunol. 138, 550 (1987) Abstract
Further Categories Containing This Product:
PRMTs, Mono- & Dimethylarginine / Related Products
 
 
ALX-106-008 Revised 23-Feb-06
NG, N'G-Dimethyl-L-arginine . dihydrochloride
Add to Clipboard
SYNONYMS SDMA . 2HCl
H-Arg(di-Me)-OH . 2HCl (symmetrical)
PRODUCT LINE Nitric Oxide Pathway
PRODUCT CATEGORY NOS Inhibitors (NOS Induction & Enzyme Activity)
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-106-008-M005   5 mg 33.00 USD Add To Cart
ALX-106-008-M025   25 mg 85.00 USD Add To Cart
Product Specification
FORMULA: C8H18N4O2 . 2HCl
MW: 202.2 . 73.0
PURITY: ≥98%
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Hygroscopic.

Product Description
Has shown not to inhibit nitric oxide synthesis, both in vitro and in vivo.
Product Specific Literature References
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure: P. Vallance, et al.; Lancet 339, 572 (1992), and references cited therein. Abstract
Further Categories Containing This Product:
PRMTs, Mono- & Dimethylarginine / Related Products
 
 
ALX-151-026 Revised 20-Jun-08
N-Acetyl-Asp-Tyr(2-malonyl)-Val-Pro-Met-Leu-NH2
Add to Clipboard
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY Tyrosine Kinase Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-151-026-M001   1 mg 90.00 USD Add To Cart
Product Specification
FORMULA: C39H57N7O14S
MW: 880.0
PURITY: ≥96% (HPLC)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in water (1mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Peptide is very unstable.
Product Description
Peptide containing a phosphotyrosyl mimetic. Effective protein tyrosine kinase inhibitor. Inhibits the phosphoinositide 3-kinase (PI(3)K) C-terminal p85 SH2 domain.
Product Specific Literature References
L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides: B. Ye, et al.; J. Med. Chem. 38, 4270 (1995) Abstract
Further Categories Containing This Product:
Peptides • Phosphoinositide 3-kinase [PI(3)K] / Related Products
 
 
ALX-151-027 Revised 17-Jan-05
N-Acetyl-Asp-Tyr(PO3H2)-Val-Pro-Met-Leu-NH2
Add to Clipboard
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY Tyrosine Kinase Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-151-027-M001   1 mg 90.00 USD Add To Cart
Product Specification
FORMULA: C36H57N7O13SP
MW: 858.9
PURITY: ≥96%
SOLUBILITY: Soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
Product Description
Phosphotyrosine containing peptide. Effective protein tyrosine kinase inhibitor. Inhibits the phosphoinositide 3-kinase (PI(3)K) C-terminal p85 SH2 domain.
Product Specific Literature References
L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides: B. Ye, et al.; J. Med. Chem. 38, 4270 (1995) Abstract
Further Categories Containing This Product:
Peptides • Phosphoinositide 3-kinase [PI(3)K] / Related Products
 
 
ALX-153-064 Revised 31-Aug-07
Caveolin-1 Scaffolding Domain Peptide
Add to Clipboard
SYNONYMS Cavtratin
AP-Cav
Pen-C1-SD
PRODUCT LINE Protein Synthesis, Modification & Degradation
PRODUCT CATEGORY Caveolae / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-153-064-M001   1 mg 140.00 USD Add To Cart
ALX-153-064-M005   5 mg 560.00 USD Add To Cart
Product Specification
SEQUENCE: H-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Asp-Gly-Ile-Trp-Lys-Ala-Ser-Phe-Thr-Thr-Phe-Thr-Val-Thr-Lys-Tyr-Trp-Phe-Tyr-Arg-OH
FORMULA: C228H335N61O49S
MW: 4746.6
APPEARANCE: ≥97% (HPLC)
SOLUBILITY: Soluble in DMSO or acentonitrile:water (50:50).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Stock solutions are stable for up to 3 months when stored at -20°C.
HANDLING: Hygroscopic. Protect from light.
HAZARD: MAY BE CARCINOGENIC. HARMFUL.
Product Description
Cell permeable peptide that blocks eNOS (NOS III) activity and cellular nitric oxide (NO) release in vitro and reduces inflammation and tumorigenesis in vivo. Caveolin-1 interacts with several lipid-modified signalling ligands, such as EGFR, eNOS, G-protein α-subunits, PKCα, H-Ras, and Src, via the C1-SD82-101 sequence.
Product Specific Literature References
Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane: T. Okamoto, et al.; J. Biol. Chem. 273, 4519 (1998) Abstract; Full Text
In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation: M. Bucci, et al.; Nat. Med. 6, 1362 (2000) Abstract; Full Text
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice: J.P. Gratton, et al.; Cancer Cell 4, 31 (2003) Abstract; Full Text
Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion: T.M. Williams, et al.; J. Biol. Chem. 279, 51630 (2004) Abstract; Full Text
Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides: P.N. Bernatchez, et al.; PNAS 102, 761 (2005) Abstract; Full Text
Further Categories Containing This Product:
Peptides • NOS Inhibitors (NOS Induction & Enzyme Activity) • NOS Regulation • Cancer Other Products
 
 
ALX-159-600 Revised 14-Jul-08
JNK Inhibitor 1 (L-stereoisomer)
Add to Clipboard
SYNONYMS L-JNKI1
c-Jun N-terminal Kinase Peptide Inhibitor 1, L-stereoisomer
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY JNK [SAPK1] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-159-600-R100   100 µl 125.00 USD Add To Cart
ALX-159-600-R200   200 µl 225.00 USD Add To Cart
Product Specification
SEQUENCE: GRKKRRQRRR-PP-RPKRPTTLNLFPQVPRSQD-amide
FORMULA: C164H286N66O40
MW: 3822.5
CONCENTRATION: 1mM
PURITY: ≥97% (HPLC)
FORMULATION: Liquid. Sterile, ready-to-use solution in PBS.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Keep on ice at all times.
POSITIVE CONTROL: Prod. No. ALX-168-009/1
Product Images
Please click on thumbnails to enlarge.
Product Description

Cell permeable JNK (c-Jun N-terminal kinase) inhibitor. For increased cell permeability the peptide was covalently linked to the 10 aa recognized by the TAT transporter. Neuroprotective agent for stroke.
Product Specific Literature References
[1] Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death: C. Bonny, et al.; Diabetes 50, 77 (2001) Abstract; Full Text
Hyperosmolarity and CD95L trigger CD95/EGF receptor association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation: R. Reinehr, et al.; FASEB J. 17, 731 (2003) Abstract
Translation inhibitors sensitize prostate cancer cells to TRAIL-induced apoptosis by activating c-Jun N-terminal kinase: N.K. Sah, et al.; J. Biol. Chem. 278, 20593 (2003) Abstract; Full Text
A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia: T. Borsello, et al.; Nat. Med. 9, 1180 (2003) Abstract
Activation of JNK in sensory neurons protects against sensory neuron cell death in diabetes and on exposure to glucose/oxidative stress in vitro: S.A. Price, et al.; Ann. NY Acad. Sci. 1010, 95 (2003)
Insulin-secreting beta-cell dysfunction induced by human lipoproteins: M.E. Roehrich, et al.; J. Biol. Chem. 278, 18368 (2003) Abstract; Full Text
Inhibition of c-Jun NH2-terminal kinase activity improves ischemia/reperfusion injury in rat lungs: M. Ishii, et al.; J. Immunol. 172, 2569 (2004) Abstract
General Information
BACKGROUND/TECHNICAL INFORMATION A protein inhibitor named IB1 has been described that competitively blocks the interaction between JNK and c-Jun, thereby inhibiting the signalling events downstream of JNK [2,3] like c-Jun, ATF2 and ELK1 phosphorylation. To convert IB1 into cell-permeable inhibitors of JNK (JNKI peptides) the minimal 20 aa inhibitory sequence of IB1 was covalently linked to the 10 amino acids recognized by TAT transporter [4].
The L-JNKI1 and the protease resistant D-JNKI1 peptides represent the only potent inhibitors that are specific for JNK (JNK1, JNK2 and JNK3). Different from chemical inhibitors that directly affect kinase activity e.g. by competing with the ATP-binding site of the protein kinase, JNKI1 rather inhibits the interaction between JNK and its substrate, resulting in a JNK K.O. phenotype. In contrast to pure diffusion the TAT-peptides are actively transported in